Charles Hugh-Jones, Volastra CEO

On­col­o­gy spe­cial­ist Volas­tra brings in PhI drug from Am­gen, nabs $60M in Se­ries A

Al­most a year af­ter ink­ing a bil­lion-dol­lar biobucks deal with Bris­tol My­ers Squibb, NYC biotech Volas­tra Ther­a­peu­tics is link­ing up with two oth­er phar­ma gi­ants …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.